Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Frontotemporal dementia: a randomised, controlled trial with trazodone.

Florence Lebert1, Willy Stekke, Christine Hasenbroekx

  • 1Memory Clinic, Lille University Hospital, Lille, France. flebert@nordnet.fr

Dementia and Geriatric Cognitive Disorders
|June 5, 2004
PubMed
Summary

Trazodone effectively treats behavioral problems in frontotemporal dementia (FTD). This study found significant improvements in irritability, agitation, and depressive symptoms, with the medication being well-tolerated by patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tanycytic degeneration impairs tau clearance and contributes to Alzheimer's disease pathology.

Cell press blue·2026
Same author

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Blood·2026
Same author

Peripheral microRNA signature in genetic frontotemporal dementia-findings from the GENFI initiative.

GeroScience·2026
Same author

A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions.

Nature genetics·2026
Same author

Clinical recognition of frontotemporal dementia with right temporal predominance: a consensus statement from the International Working Group.

Communications medicine·2025
Same author

Domain mapping of disease mutations reveals pathogenic SORL1 variants in Alzheimer's disease.

Molecular neurodegeneration·2025

Area of Science:

  • Neuroscience
  • Psychiatry

Background:

  • Behavioral disturbances are a significant challenge in managing frontotemporal dementia (FTD).
  • The frontal lobes, affected in FTD, are closely linked to the serotonergic system.
  • Trazodone is known to enhance extracellular serotonin levels in the frontal cortex.

Purpose of the Study:

  • To evaluate the efficacy of trazodone in managing behavioral symptoms associated with frontotemporal dementia (FTD).

Main Methods:

  • A randomized, double-blind, placebo-controlled, cross-over study design was employed.
  • The study included 26 evaluable patients diagnosed with FTD.
  • The Neuropsychiatry Inventory (NPI) was used to assess behavioral symptoms, with the Mini-Mental State Examination (MMSE) also administered.

Related Experiment Videos

Main Results:

  • Trazodone significantly reduced the total Neuropsychiatry Inventory (NPI) score (p = 0.028).
  • Over 50% reduction in NPI score was achieved by 10 patients receiving trazodone.
  • Improvements were noted in specific symptoms including irritability, agitation, depressive symptoms, and eating disorders.
  • No significant changes were observed in Mini-Mental State Examination (MMSE) scores.

Conclusions:

  • Trazodone demonstrates effectiveness in treating behavioral symptoms of frontotemporal dementia (FTD).
  • The medication was well-tolerated by participants in this study.
  • These findings suggest trazodone as a potential therapeutic option for FTD-related behavioral issues.